HARDMAN & CO RESEARCH Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building

Directive transparence : information réglementée

15/09/2022 14:52

Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building

15-Sep-2022 / 13:52 GMT/BST

Hardman & Co Research on Shield Therapeutics (STX):

Accrufer momentum building

Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the initial challenge was to greatly improve market awareness of its differentiating features as an oral ID drug. Although the initial uptake was slower than anticipated, there are clear signs in the 1H’22 results that momentum is building. During 2H’22, management will continue to investigate potential sources of capital needed to accelerate prescription (Rx) growth and obtain sales traction.


Please click on the link below for the full report:


If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
1 Frederick’s Place




Follow us on Twitter @HardmanandCo


Martin Hall

+44(0)203 693 7075




Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

1443655  15-Sep-2022